Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7879783 | 1.00 | DRD2 (0.50) | DRD2DRD3SLC6A3KCNH2TAAR1 | |
| Hydrochloric Acid SCHEMBL29564721 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL966629 | 0.98 | — | — | |
| SCHEMBL12610007 | 0.84 | — | — | |
| SCHEMBL12610008 | 0.84 | — | — | |
| SCHEMBL15111596 | 0.81 | — | — | |
| SCHEMBL15111808 | 0.81 | — | — | |
| SCHEMBL15111597 | 0.81 | — | — | |
| SCHEMBL23472129 | 0.81 | DRD2 (0.64) | DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL16443901 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113135835-A | Method for exciting C-C bond breaking acylation and application | 广州中医药大学(广州中医药研究院) | 2021-07-20 | — | — | CN | claimed |
| EP-4146220-B1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250388574-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12319691-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-12252489-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2025-03-18 | — | — | US | disclosed |
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240190863-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240124446-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2024-04-18 | — | — | US | disclosed |
| CN-115215764-B | Preparation method of deuterated aromatic nitrile compound | 浙大宁波理工学院 | 2023-12-08 | — | — | CN | disclosed |
| CN-115215764-A | Preparation method of deuterated aromatic nitrile compound | 浙大宁波理工学院 | 2022-10-21 | — | — | CN | disclosed |
| CN-113135835-B | Method for exciting C-C bond breaking acylation and application | 广州中医药大学(广州中医药研究院) | 2022-07-01 | — | — | CN | disclosed |
| CN-113135835-A | Method for exciting C-C bond breaking acylation and application | 广州中医药大学(广州中医药研究院) | 2021-07-20 | — | — | CN | disclosed |
| CN-103333275-B | With the polymkeric substance of functionalized with nitrile compounds comprising protected amino | BRIDGESTONE CO., LTD. (JP) | 2015-07-29 | — | — | CN | disclosed |
| CN-103333275-A | Polymers functionalized with nitrile compounds containing a protected amino group | BRIDGESTONE CORP | 2013-10-02 | — | — | CN | disclosed |
| CN-102361887-B | Polymers functionalized with nitrile compounds containing a protected amino group | BRIDGESTONE CORP | 2013-06-26 | — | — | CN | disclosed |
| US-20120059165-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI (FR) | 2012-03-08 | — | — | US | disclosed |
| CN-102361887-A | Polymers functionalized with nitrile compounds containing a protected amino group | BRIDGESTONE CORP | 2012-02-22 | — | — | CN | disclosed |
| EP-2406254-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI (FR) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010104193-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059165-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | HRH4, HNMT, CYP3A4 | DRD2 183/4885DRD3 437/4885SLC6A3 124/4885 |
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | ENPP2, SSB, PLPBP | DRD2 4540/4885DRD3 4063/4885SLC6A3 959/4885 |
| US-12252489-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | DRD2 1382/4885DRD3 2911/4885SLC6A3 3789/4885 |
| US-20240190863-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | DRD2 1382/4885DRD3 2911/4885SLC6A3 3789/4885 |
| US-12319691-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | DRD2 1052/4885DRD3 2484/4885SLC6A3 3552/4885 |
| US-20240124446-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | DRD2 1052/4885DRD3 2484/4885SLC6A3 3552/4885 |
| US-20250388574-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FCER2, HAVCR2 | DRD2 2048/4885DRD3 3053/4885SLC6A3 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.